Dublin, Dec. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
Global Gynecology Partnering 2010-2021: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
- Trends in Gynecology partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Gynecology partnering agreement structure
- Gynecology partnering contract documents
- Top Gynecology deals by value
- Most active Gynecology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.
The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report Scope
Global Gynecology Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide.
Global Gynecology Partnering 2010 to 2021 includes:
- Trends in Gynecology dealmaking in the biopharma industry since 2010
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Gynecology deal contract documents
- Comprehensive access to over 400 Gynecology deal records
- The leading Gynecology deals by value since 2010
- Most active Gynecology dealmakers since 2010
The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.
In Global Gynecology Partnering 2010 to 2021, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Gynecology Partnering 2010-2021 report provides comprehensive access to available deals and contract documents for over 400 gynecology deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Benefits
Global Gynecology Partnering 2010-2021: Deal trends, players and financials provides the reader with the following key benefits:
- In-depth understanding of Gynecology deal trends since 2010
- Access Gynecology deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Gynecology partner companies
- Comprehensive access to over 400 links to actual Gynecology deals entered into by the world's biopharma companies
- In-depth review of Gynecology deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Gynecology opportunities
- Uncover companies actively partnering Gynecology opportunities
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication
Chapter 3 -Financial deal terms for Gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for Gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates
Chapter 4 - Leading Gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in Gynecology partnering
4.3. List of most active dealmakers in Gynecology
4.4. Top Gynecology deals by value
Chapter 5 - Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available
Chapter 6 - Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gynecology therapeutic target
Companies Mentioned
- Osivax
- Dewpoint Therapeutics
- Elanix Biotechnologies
- University of Oxford
- University of California San Francisco
- Psyche Systems
- Medesole Healthcare and Trading
- Fannin
- MSD
- Beijing Genomics Institute (BGI)
- University of Queensland
- twoXAR
- Vanderbilt University
- Dr. Jennifer R. Berman
- KV Pharmaceutical
- United Nations Children Fund
- DySIS Medical
- Altavant Sciences
- Julphar
- Accord Healthcare
- Galaxy Pharma
- Amgen
- Healthcare Royalty Partners
- American Dental Association
- Premier Healthcare Alliance
- 23andMe
- Scholar Rock
- Gland Pharma
- SRS Medical
- Juniper Pharmaceuticals
- Bavarian Nordic
- Biomnis
- Titan Medical
- Lumara Health
- National Institute of Allergy and Infectious Diseases
- ZenTech
- Chinese Academy of Sciences
- Smith & Nephew
- Biodar plus
- Roche
- Fogarty Institute for Innovation
- Merck Serono
- Joint Venture Partner Group
- National Human Genome Research Institute
- Genea Biomedx
- Richard Wolf Medical Instruments
- AntibioTx
- Conceptus
- Vitro Biopharma
- Fuisz Pharma
For more information about this report visit https://www.researchandmarkets.com/r/wgq0ab
